Welcoming 2022 with a celebration of the past year's accomplishments.

Congratulations David!

Welcome Jigar and Jeff! Very excited to be working with you!

Ambys is hiring! We have an exciting opportunity for an experienced scientist with flow cytometry expertise to join our Bioanalytical and Assay Development team. Click here to learn more: grnh.se/e7b018662us #celltherapy #biotechnology #flowcytometry #workatambys #ambysians

Welcome Septerna! x.com/thirdrockv/sta…

Our Chief Business Officer Mike Boretti is excited to add an Associate Director of BD & Strategic Alliances to his team! We're looking forward to the progress and growth this year has to offer. Check out the position below. bit.ly/3ACVyya

George Xu started as a senior associate at TRV helping incubate new companies, and now serves as director of corporate strategy and portfolio development at our newest portco, @Septerna_Inc! Apply to be an associate at Third Rock here: bit.ly/3om4Rxz

My son and his dance company performing this weekend! ➡️➡️Feet make music, too, in Subject:Matter’s ‘Songbook’ at the Somerville Theatre bostonglobe.com/2022/02/03/art…

We are grateful to have an incredible group of female leaders driving our work to reshape the way disease is viewed and treated by leveraging the power of #biomolecularcondensates. #InternationalDayofWomenandGirlsinScience #February11 #WomenInSTEM

Congratulations to @GBT_news for receiving EU approval for Oxbryta today! Sickle cell disease is one of the most prevalent genetic diseases in Europe, and now these patients have a new therapeutic option.

Renewed! Amazing retreat w my friends! #womeninbio #womaninscience #leadership #thankful Rachel Cynthia Clayton Susanna

Today on #RareDiseaseDay we had the privilege of meeting Molly Anderson, whose family suffers from a genetic form of gastric cancer. Thank you to Molly for sharing your story, inspiring patient advocates globally, and motivating us to continue serving patients in all that we do.

Congratulations to Bristol Myers Squibb and TRV portco MyoKardia on their FDA approval for Camzyos, an oral heart disease drug. Hypertrophic cardiomyopathy (#HCM) is one of the leading causes of sudden cardiac death in young people. This is fantastic news for patients and their families!

We're excited to announce the completion of our Series B financing, advancing our novel #drugdiscovery platform to develop precision medicines for patients in need. Read more here: businesswire.com/news/home/2022…

Welcome Terremoto!

We just launched Fund VI with $1.1 billion and are very excited to go create more companies! thirdrockventures.com/uploads/press-…

Congratulations Dodzie!

TRV Partner David Kaufman shares thoughts about his journey and experiences he's had throughout his career. Thank you BIOS for hosting this great conversation: x.com/bios_community…

Congrats Andrea van Elsas

Excited to see what this team accomplishes!